MX2022011258A - Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas. - Google Patents
Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas.Info
- Publication number
- MX2022011258A MX2022011258A MX2022011258A MX2022011258A MX2022011258A MX 2022011258 A MX2022011258 A MX 2022011258A MX 2022011258 A MX2022011258 A MX 2022011258A MX 2022011258 A MX2022011258 A MX 2022011258A MX 2022011258 A MX2022011258 A MX 2022011258A
- Authority
- MX
- Mexico
- Prior art keywords
- therapy
- nirogacestat
- bcma
- directed
- combination therapy
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- VFCRKLWBYMDAED-REWPJTCUSA-N (2s)-2-[[(2s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-n-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide Chemical compound O=C([C@@H](N[C@@H]1CC2=C(F)C=C(F)C=C2CC1)CCC)NC1=CN(C(C)(C)CNCC(C)(C)C)C=N1 VFCRKLWBYMDAED-REWPJTCUSA-N 0.000 title 1
- 229950001637 nirogacestat Drugs 0.000 title 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 abstract 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 abstract 2
- LXEYYZYDWLAIPW-KBVFCZPLSA-N (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide dihydrobromide Chemical compound Br.Br.CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C LXEYYZYDWLAIPW-KBVFCZPLSA-N 0.000 abstract 1
- 208000023761 AL amyloidosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente descripción proporciona métodos para tratar el cáncer o la amiloidosis de cadena ligera en un sujeto que lo necesite, que comprenden administrar una terapia combinada que comprende una cantidad eficaz de la Forma A del dihidrobromuro de nirogacestat y una terapia dirigida al antígeno de maduración de linfocitos B (BCMA, por sus siglas en inglés) al sujeto y los usos de estas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062989372P | 2020-03-13 | 2020-03-13 | |
PCT/US2021/022177 WO2021183934A1 (en) | 2020-03-13 | 2021-03-12 | A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022011258A true MX2022011258A (es) | 2023-01-11 |
Family
ID=75396879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022011258A MX2022011258A (es) | 2020-03-13 | 2021-03-12 | Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230121547A1 (es) |
EP (1) | EP4132515A1 (es) |
JP (1) | JP2023517243A (es) |
KR (1) | KR20230009873A (es) |
CN (1) | CN115916188A (es) |
AR (1) | AR121566A1 (es) |
AU (1) | AU2021236340A1 (es) |
BR (1) | BR112022018251A2 (es) |
CA (1) | CA3171267A1 (es) |
CL (1) | CL2022002479A1 (es) |
CO (1) | CO2022014388A2 (es) |
IL (1) | IL296075A (es) |
MX (1) | MX2022011258A (es) |
PE (1) | PE20230614A1 (es) |
TW (1) | TW202200132A (es) |
WO (1) | WO2021183934A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4396159A1 (en) | 2021-09-01 | 2024-07-10 | Springworks Therapeutics, Inc. | Synthesis of nirogacestat |
WO2023064872A1 (en) * | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
CN118338900A (zh) * | 2021-11-05 | 2024-07-12 | 斯普林渥克斯治疗有限公司 | 含尼罗加司他的组合物和治疗 |
AU2022396239A1 (en) * | 2021-11-23 | 2024-06-06 | Teva Pharmaceuticals International Gmbh | Solid state forms of nirogacestat salts |
US11872211B2 (en) | 2022-05-20 | 2024-01-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
US12036207B2 (en) | 2022-05-20 | 2024-07-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
US11951096B2 (en) | 2022-05-20 | 2024-04-09 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
WO2024183739A1 (zh) * | 2023-03-09 | 2024-09-12 | 苏州科睿思制药有限公司 | 尼罗司他二氢溴酸盐的晶型及其制备方法和用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015120065A1 (en) * | 2014-02-05 | 2015-08-13 | The Trustees Of Columbia University In The City Of New York | Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides |
BR112018001480A2 (pt) * | 2015-07-24 | 2018-09-11 | Oncotracker Inc | moduladores de gama secretase para o tratamento de disfunção do sistema imunológico |
US11845803B2 (en) * | 2017-02-17 | 2023-12-19 | Fred Hutchinson Cancer Center | Combination therapies for treatment of BCMA-related cancers and autoimmune disorders |
EP3615055A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
JP7233425B2 (ja) * | 2017-11-06 | 2023-03-06 | ジュノー セラピューティクス インコーポレイテッド | 細胞療法とガンマセクレターゼ阻害剤との組み合わせ |
US11970542B2 (en) * | 2017-11-08 | 2024-04-30 | Fred Hutchinson Cancer Center | Bispecific antibodies specific for treating hematological malignancies |
US20210069194A1 (en) * | 2018-01-17 | 2021-03-11 | Mingsight Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer |
JP2021526517A (ja) * | 2018-05-24 | 2021-10-07 | アヤラ ファーマシューティカルズ インコーポレイテッド | ビスフルオロアルキル−1,4−ベンゾジアゼピノン化合物および免疫療法剤を含む組成物ならびにそれらの使用方法 |
US11492409B2 (en) * | 2018-06-01 | 2022-11-08 | Novartis Ag | Binding molecules against BCMA and uses thereof |
KR20210150488A (ko) * | 2019-04-10 | 2021-12-10 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 항 bcma 항체 및 감마 세크레타제 억제제의 조합 요법 |
CA3150424A1 (en) * | 2019-08-09 | 2021-02-18 | Pfizer Inc. | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof |
-
2021
- 2021-03-12 AR ARP210100641A patent/AR121566A1/es unknown
- 2021-03-12 JP JP2022554833A patent/JP2023517243A/ja active Pending
- 2021-03-12 KR KR1020227034017A patent/KR20230009873A/ko active Search and Examination
- 2021-03-12 WO PCT/US2021/022177 patent/WO2021183934A1/en active Application Filing
- 2021-03-12 IL IL296075A patent/IL296075A/en unknown
- 2021-03-12 CA CA3171267A patent/CA3171267A1/en active Pending
- 2021-03-12 BR BR112022018251A patent/BR112022018251A2/pt unknown
- 2021-03-12 CN CN202180034598.4A patent/CN115916188A/zh active Pending
- 2021-03-12 TW TW110108930A patent/TW202200132A/zh unknown
- 2021-03-12 EP EP21716907.7A patent/EP4132515A1/en active Pending
- 2021-03-12 US US17/906,089 patent/US20230121547A1/en active Pending
- 2021-03-12 MX MX2022011258A patent/MX2022011258A/es unknown
- 2021-03-12 PE PE2022001961A patent/PE20230614A1/es unknown
- 2021-03-12 AU AU2021236340A patent/AU2021236340A1/en active Pending
-
2022
- 2022-09-12 CL CL2022002479A patent/CL2022002479A1/es unknown
- 2022-10-10 CO CONC2022/0014388A patent/CO2022014388A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023517243A (ja) | 2023-04-24 |
TW202200132A (zh) | 2022-01-01 |
KR20230009873A (ko) | 2023-01-17 |
CL2022002479A1 (es) | 2023-08-18 |
CO2022014388A2 (es) | 2023-02-16 |
IL296075A (en) | 2022-11-01 |
US20230121547A1 (en) | 2023-04-20 |
AR121566A1 (es) | 2022-06-15 |
WO2021183934A1 (en) | 2021-09-16 |
EP4132515A1 (en) | 2023-02-15 |
AU2021236340A1 (en) | 2022-09-29 |
BR112022018251A2 (pt) | 2022-11-08 |
CA3171267A1 (en) | 2021-09-16 |
PE20230614A1 (es) | 2023-04-14 |
CN115916188A (zh) | 2023-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022011258A (es) | Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas. | |
SG136804A1 (en) | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications | |
MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
MX2020009773A (es) | Terapia de combinacion. | |
MX2020006042A (es) | Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas. | |
NO20054988D0 (no) | Preparater og metoder for behandling av cancer | |
TW200501960A (en) | Synergistic kits and compositions for treating cancer | |
CY1113287T1 (el) | Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα | |
MX2021002888A (es) | Combinaciones farmacéuticas para el tratamiento de tumores que comprenden un anticuerpo anti cúmulo de diferenciación 19 (cd19) y una célula asesina natural. | |
MX2020001727A (es) | Terapia de combinacion. | |
PA8574001A1 (es) | Uso de docetaxel en combinacion con doxorrubicina y ciclofosfamida como terapia adyuvante | |
CY1111565T1 (el) | Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11 | |
MX2013010770A (es) | Tratamiento de tumores solidos. | |
MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
RU2012147340A (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR | |
JOP20210245A1 (ar) | طرق لعلاج الداء النشواني من النوع خفيف السلسلة | |
EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
MX2024004899A (es) | Compuestos de piperidinilpirazina-carboxamida para tratar y prevenir el cancer y para degradar btk. | |
DK1689404T3 (da) | Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer | |
EA202190457A1 (ru) | Конъюгаты для применения в способах лечения рака | |
MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
MX2021006778A (es) | Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion. | |
MX2022001450A (es) | Metodo de tratamiento del cancer. |